<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is a cluster of <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp>, including impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> and abdominal <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It is a precursor to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and a powerful independent risk factor for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Lifestyle changes, such as a diet high in saturated fats and a lack of physical exercise, have contributed to a worldwide increase in the prevalence of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and its associated complications </plain></SENT>
<SENT sid="3" pm="."><plain>Identification and effective management of patients with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is important to reduce their risk of subsequent disease </plain></SENT>
<SENT sid="4" pm="."><plain>Lifestyle modifications are an essential first step, and <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering therapy may also be required to achieve the <z:chebi fb="23" ids="18059">lipid</z:chebi> goals set out in current treatment guidelines </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="35664">Statins</z:chebi> are the most effective class of <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering drugs </plain></SENT>
<SENT sid="6" pm="."><plain>Recent studies in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> or the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> have shown that <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> was more effective than <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, <z:chebi fb="0" ids="9150">simvastatin</z:chebi> or pravastatin in reducing <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> and enabling patients to reach <z:chebi fb="23" ids="18059">lipid</z:chebi> goals </plain></SENT>
</text></document>